LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
… RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the … cause loss of functional usherin protein that causes the disease. QR-421a is designed to exclude the genetic defect …
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th
… RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the … RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10 and …